Annovis Bio (id:10145 ANVS)
6.65 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 9:39:08 PM)
Exchange closed, opens in 11 hours 50 minutes
About Annovis Bio
Market Capitalization 96.17M
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
| Headquarters (address) |
101 Lindenwood Drive Malvern 19355 PA United States |
| Phone | (484) 875-3192 |
| Website | https://www.annovisbio.com |
| Employees | 6 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ANVS |
| Exchange | New York Stock Exchange |
| Currency | USD |
| 52 week range | 4.53 - 22.49 |
| Market Capitalization | 96.17M |
| P/E trailing | -1.07 |
| P/E forward | -3.85 |
| Price/Book | 13.10 |
| EPS | -4.22 |
| EPS United States (ID:6, base:3401) | 24.23 |